3 assets in Myalgic Encephalomeyelitis/Chronic Fatigue Syndrome

Therapeutic assets addressing Myalgic Encephalomeyelitis/Chronic Fatigue Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Naltrexone Myalgic Encephalomeyelitis/Chronic Fatigue Syndrome	Brigham and Women's Hospital	P2	CCC (53)
Pyridostigmine Myalgic Encephalomeyelitis/Chronic Fatigue Syndrome	Brigham and Women's Hospital	P2	CCC (53)
Autologous Leukocytes, 89Zr-Oxine Labeled Myalgic Encephalomeyelitis/Chronic Fatigue Syndrome	University of Alabama at Birmingham	P1	CC (43)